Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy

Clinical Transplantation

Volumn 20, Issue 2, 2006, Pages 206-210

  Nath, Dilip S ^a   Kalis, Ann ^a   Nelson, Susan ^a   Payne, William D ^a   Lake, John R ^a   Humar, Abhinav ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Hepatitis B; Immunoglobulin therapy; Liver transplants

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BASILIXIMAB; BILIRUBIN; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIGEN; HEPATITIS E ANTIGEN; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RNA; TACROLIMUS; TENOFOVIR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN DETECTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CADAVER; CLINICAL ARTICLE; DRUG DOSE REGIMEN; DRUG TOLERANCE; FOLLOW UP; GRAFT SURVIVAL; HEMATOMA; HEPATITIS B; HEPATITIS B VIRUS; HERNIA INCARCERATION; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RNA ANALYSIS; SEROLOGY; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADULT; FOLLOW-UP STUDIES; HEPATITIS B; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; LIVER TRANSPLANTATION; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33646020354     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2005.00467.x     Document Type: Article

References (19)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997: 37: 1733.
2. O'Grady JG, Smith HM, Davies SE et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992: 14: 104. 104.
3. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: A concise review. Hepatology 2000: 32: 1189.
4. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993: 329: 1842.
5. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001: 120: 1828.
6. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver TransplanS 2004: 10 (Suppl. 2): s74.
7. Asmuth DM, Nguyen HH, Melcher GP, Cohen SH, Pollard RB. Treatment for hepatitis B. Clin Infec Dis 2004: 39: 1353.
8. Han SH, Martin P, Edelstein M et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transplant 2003: 9: 182.
9. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998: 339: 61.
10. Liaw YF. Results of lamivudine trials in Asia. J Hepatol 2003: 39: S111.
11. Bock CT, Tillman HL, Torresi J et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002: 122: 264.
12. Westland CE, Yang H, Delaney WE IV et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003: 38: 96.
13. Villeneuve JP, Durantel D, Durantel S et al. Selection of a hepatitis B virus train resistant to adefovir in a liver transplantation patient. J Hepatol 2003: 39: 1085.
14. Terrault NA, Zhou S, Combs C et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunglobuin. Hepatology 1996: 24: 1327.
15. Di Paolo D, Tiscone G, Piccolo P, Lenci I, Zazza S, Angelico M. Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: A highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 2004: 77: 1203.
16. Terrault NA, Zhou S, McCory RW et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998: 28: 555.
17. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transplant 2000: 6: 429.
18. Yao FY, Osorio RW, Roberts JP et al. Intramuscular hepatitis B immune globin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transplant Surg 1999: 5: 491.
19. Lee WM. Hepatitis B virus infection. N Engl J Med 1997: 37: 1733.